

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

NOVARTIS PHARMACEUTICALS  
CORPORATION and NOVARTIS AG,

Plaintiffs,

v.

PAR PHARMACEUTICAL, INC.,

Defendant.

C.A. No. 14-1289-RGA

C.A. No. 14-1494-RGA

C.A. No. 15-0078-RGA

**NOTICE OF APPEAL**

Notice is hereby given that Plaintiffs Novartis Pharmaceuticals Corporation and Novartis AG appeal to the United States Court of Appeals for the Federal Circuit from the Final Judgment entered on May 16, 2017 in Civil Actions Nos. 14-1289-RGA (D.I. 180), 14-1494-RGA (D.I. 108) and 15-0078-RGA (D.I. 107) as it relates to the validity of U.S. Patent No. 5,665,772, and all underlying orders and findings made prior to, during, and after trial concerning U.S. Patent No. 5,665,772, including but not limited to the Amended Trial Opinion entered on April 3, 2017 in Civil Action No. 14-1289-RGA (D.I. 171).

Dated: June 14, 2017

McCARTER & ENGLISH, LLP

/s/ Daniel M. Silver

Daniel M. Silver (#4758)

Renaissance Centre

405 N. King Street, 8th Floor

Wilmington, Delaware 19801

(302) 984-6300

[dsilver@mccarter.com](mailto:dsilver@mccarter.com)

*Attorneys for Plaintiffs*

Of Counsel:

Nicholas N. Kallas  
Christopher E. Loh  
Charlotte Jacobsen  
Christina Schwarz  
FITZPATRICK, CELLA, HARPER & SCINTO  
1290 Avenue of the Americas  
New York, New York 10104-3800  
(212) 218-2100  
[nkallas@fchs.com](mailto:nkallas@fchs.com)  
[cloh@fchs.com](mailto:cloh@fchs.com)  
[cjacobsen@fchs.com](mailto:cjacobsen@fchs.com)  
[cschwarz@fchs.com](mailto:cschwarz@fchs.com)